Zuppan C W, Beckwith J B, Weeks D A, Luckey D W, Pringle K C
Department of Pathology, Loma Linda University, California.
Cancer. 1991 Jul 15;68(2):385-94. doi: 10.1002/1097-0142(19910715)68:2<385::aid-cncr2820680229>3.0.co;2-t.
Preoperative chemotherapy is being used with increasing frequency in the US for the management of selected children with Wilms' tumor, despite relatively limited knowledge as to the effects of such therapy on tumor histologic features. The authors reviewed pathologic material from all preoperatively treated unilateral Wilms' tumors registered on the third National Wilms' Tumor Study. Preoperative therapy was associated with increased ambiguity of tumor stage. The prevalence of anaplasia in the 83 evaluable specimens was similar to, although slightly increased over, that in comparable high-stage untreated Wilms' tumors (11% versus 5% to 8%), and it appeared to retain its adverse connotations. These data also suggest that alterations of tumor character and distribution by therapy provide useful prognostic information. All 17 children whose residual viable tumor was limited to intrarenal sites at the time of resection were alive and disease-free at last follow-up. Extensive (greater than 90%) tumor necrosis, low mitotic activity, and high degrees of differentiation of residual tumor were also associated with favorable outcomes. Although careful utilization of preoperative chemotherapy can be of value in children with otherwise difficult-to-manage Wilms' tumors, the potential benefits of preoperative tumor bulk reduction must be weighed against the risk of overtreatment or undertreatment as a result of increased ambiguity of tumor stage.
在美国,尽管对于术前化疗对肿瘤组织学特征的影响了解相对有限,但越来越频繁地将其用于治疗特定的肾母细胞瘤患儿。作者回顾了第三次全国肾母细胞瘤研究中登记的所有术前接受治疗的单侧肾母细胞瘤的病理资料。术前治疗与肿瘤分期的不确定性增加有关。在83份可评估标本中,间变的发生率与未接受治疗的高分期肾母细胞瘤相当,尽管略有增加(分别为11%和5%至8%),而且似乎仍具有不良预后意义。这些数据还表明,治疗引起的肿瘤特征和分布改变提供了有用的预后信息。所有17例在切除时残余存活肿瘤局限于肾内的患儿在最后一次随访时均存活且无疾病。广泛(大于90%)的肿瘤坏死、低有丝分裂活性以及残余肿瘤的高分化程度也与良好预后相关。尽管谨慎使用术前化疗对于那些难以治疗的肾母细胞瘤患儿可能有价值,但术前减少肿瘤体积的潜在益处必须与因肿瘤分期不确定性增加导致过度治疗或治疗不足的风险相权衡。